Dr E. David G. McIntosh AM is an Australian paediatrician (with dual Australian and British nationality), vaccinologist and infectious disease specialist. David joined Takeda Vaccines as Senior Director Policy and Scientific Affairs (Vaccines) on 1 September 2015 and became Regional Medical Affairs Lead, Latin America on 7 December 2015.Previously, David worked on pneumococcal conjugate vaccines, the intra-nasal cold-adapted influenza vaccine, the antibiotics tigecycline and piperacillin-tazobactam and the anti-parasitic agent moxidectin, for the treatment of River Blindness (onchocerciasis) in Africa.He originally trained as a medical doctor in Sydney, Australia and specialised in paediatric infectious diseases and public health. His early work was in Papua New Guinea, the Northern Territory of Australia, Peru, Argentina, New Zealand and the UK.His early research was on early-onset Group B streptococcal in Sydney. His MPH treatise involved the study of chronic suppurative otitis media in Australian Aborigines. His PhD thesis described the molecular epidemiology of hepatitis B virus in recent immigrant families to Australia. He co-authored the landmark 50-year follow-up of the original congenital rubella syndrome patients. His post-doctoral work was on gene therapy for hepatitis, in the Department of Medicine at Imperial College, a university in London, UK.He has written chapters on hepatitis A and hepatitis B vaccination, pneumococcal vaccination, paediatric clinical pharmacology, paediatric clinical trials, post-infectious sequelae and long-term consequences of infectious diseases, efflux pumps, respiratory infections and meningococcal vaccination. In May 2012 he obtained another post-graduate degree, a Master’s degree in Medical Law and Ethics (LLM), the dissertation for which was on the subject of maternal immunisation.David is an Honorary Clinical Senior Lecturer at Imperial College, London, Honorary Professor at the Scientific Center for Children’s Health, Moscow, Russia and Chair Allergy and Clinical Immunology at the I. M. Sechenov First Moscow State Medical University. He is an ECDC Expert and member of the UK Parliamentary and Scientific Committee. On 13 June 2011 in the Queen’s Birthday Honours List he was appointed as a Member in the General Division of the Order of Australia, within the Australian Honours System. He holds the following qualifications: MBBS, MPH, LLM, PhD, FAFPHM, FRACP, FRCP&CH, FFPM, DRCOG, DCH, Dip Pharm Med.
Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals—the example of serogroup B meningococcal infectionTherapeutic Advances in Vaccines
2014In countries with established programmes for vaccination of infants, toddlers and adolescents with meningococcal conjugate vaccines, serogroup B invasive meningococcal disease remains the major cause of septicaemia and meningitis in the paediatric and adolescent age groups. Novartis has developed a serogroup B meningococcal vaccine, 4CMenB, to meet this need ...
2011Meningococcal disease is characterized by a marked variation in incidence and serogroup distribution by region and over time. In several European countries, Canada and Australia, immunization programs, including universal vaccination of infants or toddlers with catch- ...
2011Streptococcus pneumoniae is the leading cause of vaccine-preventable deaths among children younger than 5 years of age worldwide. The 7-valent pneumococcal conjugate vaccine (PCV7) is currently licensed in more than 90 countries and has contributed to ...
Characterization of Clostridium botulinum strains associated with an infant botulism case in the United KingdomJournal of Clinical Microbiology
2005The sixth case of infant botulism in the United Kingdom was reported in 2001. The case was caused by a type B strain of Clostridium botulinum. Strains of C. botulinum were isolated from the baby's feces and from foodstuffs in the household in an attempt to ...
The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccineVaccine
2003We modelled the epidemiology and cost of pneumococcal disease in children in the UK and the cost-effectiveness of immunisation with 7-valent pneumococcal conjugate vaccine (PCV). We estimated the incidence of pneumococcal meningitis, pneumococcal ...
1993Respiratory syneytial virus (RSV) has two major antigenic groups, A and B. There is disagreement as to whether or not there is a difference in the clinical severity of disease caused by the two RSV groups. This 3-year prospective study of infants and children with ...
Area of Expertise
Royal College of Physicians : Pharmaceutical Medicine